On November 20, 2025, the Honorable Denise Cote of the United States District Court for the Southern District of New York granted preliminary approval of a settlement reached on behalf of investors in In re Applied Therapeutics Securities Litigation, No. 1:24-cv-09715. The settlement provides for a settlement fund of $15 million in cash and warrants to purchase up to one million shares of Applied Therapeutics Inc. common stock at an exercise price of $0.48 per share, the closing price of Applied Therapeutics common stock on August 19, 2025, the date the settlement was reached. The settlement resolves claims that the Company misled investors regarding its 2024 New Drug Application for the drug candidate Govorestat.
In preliminarily approving the settlement, Judge Cote found that the agreement “appears to fall within the range of possible approval and is therefore sufficiently fair, reasonable, and adequate to warrant providing notice of the settlement to the class.” The proposed class consists of investors who purchased Applied Therapeutics common stock on U.S. exchanges between January 3, 2024 and December 2, 2024.
A Court-approved postcard notice will be mailed by December 19, 2025. A settlement website, which will contain downloadable copies of the full longform notice, claim form, and important court documents, will also be launched by December 19, 2025. Class members must submit a timely and valid claim form on or before April 8, 2026 in order to be eligible for a share of the net settlement fund.
The Court has scheduled a hearing to consider final approval of the Settlement for March 19, 2025 at 11:00 a.m. Class members are not required to appear at the hearing.
Wolf Popper LLP serves as Court-appointed Lead Counsel for the class.